EP1228146A1 - Compositions copolymeres de silane renfermant des principes actifs - Google Patents

Compositions copolymeres de silane renfermant des principes actifs

Info

Publication number
EP1228146A1
EP1228146A1 EP00930553A EP00930553A EP1228146A1 EP 1228146 A1 EP1228146 A1 EP 1228146A1 EP 00930553 A EP00930553 A EP 00930553A EP 00930553 A EP00930553 A EP 00930553A EP 1228146 A1 EP1228146 A1 EP 1228146A1
Authority
EP
European Patent Office
Prior art keywords
agents
active agent
coating
copolymer
silane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00930553A
Other languages
German (de)
English (en)
Inventor
Richard N. Terry
Kevin Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CR Bard Inc
Original Assignee
CR Bard Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/026155 external-priority patent/WO2000027897A2/fr
Application filed by CR Bard Inc filed Critical CR Bard Inc
Publication of EP1228146A1 publication Critical patent/EP1228146A1/fr
Withdrawn legal-status Critical Current

Links

Definitions

  • the invention relates generally to biocompatible, hydrophilic compositions, their manufacture, and their use for coating surfaces, such as silicone, glass, and other difficult to coat surfaces. More specifically, the invention relates to hydrophilic coatings which are elastic when dry and resist wet abrasion, and to their use as coatings for articles, such as medical devices, particularly articles composed of polydimethylsiloxane (silicone) rubber.
  • compositions containing an active agent are useful, for example, as antimicrobials, pharmaceuticals, diagnostic agents, herbicides, insecticides, antifoulants, and the like.
  • Such devices include guidewires; catheters, including Foley, angioplasty, diagnostic, and balloon catheters; implant devices; contact lenses; IUDs; peristaltic pump chambers; endotracheal tubes; gastroenteric feed tubes; arteriovenous shunts; condoms; and oxygenator and kidney membranes. It is necessary for the surface of these medical devices to have a low coefficient of friction to prevent injury, irritation, or inflammation to the patient and to facilitate medical and surgical procedures.
  • the appropriate level is one at which the device is very slippery when contacted with the patient's moist tissue, but is not so slippery when dry that it is difficult for medical personnel to handle.
  • Current materials from which such medical devices are made include silicone rubber, Teflon®, polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polyurethane (PU), polytetrafluoroethylene (PTFE), Nylon®, polyethylene terephthalate (PET), and glass. These materials, however, lack the desired degree of slipperiness.
  • One approach to providing medical devices with more desirable surface characteristics is to coat the devices made from existing materials with various coating compositions. These coatings may be applied by spraying or painting the coating on the device or by dipping the device in a solution of the coating.
  • Some substances which have been employed as coatings are Teflon®, silicone fluid, glycerin, mineral oils, olive oil, K-Y jelly, and fluorocarbons. However, these substances have not been entirely satisfactory because they lack hydrophilicity, are not retained on the device surface during the period of use, are non-durable, or exhibit inadequate retention of lubricity.
  • Hydrophilic polymer and hydrogel coatings were an improvement to the art and have been used successfully to provide coatings for many of the easier to coat substrates, such as polyurethane and latex rubber. These coatings, however, are poorly adherent to silicone rubber and wash off when the device is wetted.
  • PEO and PEG are friction-reducing, blood-compatible polymers that are commercially available in a variety of molecular weights. Both have been used in combination with various other materials to produce lubricious coatings for medical devices.
  • coatings incorporating PEO and isocyanates are known in the art (U.S. Patents 5,459,317, 4,487,808, and 4,585,666 to Lambert; and U.S. Patent 5,558,900 to Fan et al.).
  • polyols may be incorporated into such PEO/isocyanate coatings to produce a crosslinked polyurethane (PU) network entrapping the PEO (U.S. Patents 5,077,352 and 5,179,174 to Elton).
  • PEO has also been combined with structural plastic having a high molecular weight to produce a coating with reduced friction (U.S. Patent 5,041,100 to Rowland).
  • PVP polyvinyl pyrrolidone
  • PVP may be used as a coating alone or in combination with other polymers.
  • polyvinyl pyrrohdone may be bonded to a substrate by thermally activated free radical initiators, UV tight activated free-radical initiators, or E-beam radiation (WO 89/09246).
  • E-beam radiation can be deleterious to some of the materials used in medical devices.
  • PVP may be used in conjunction with other polymers.
  • One such coating is made from PVP and glycidyl acrylate. This coating requires the presence of amino groups on the surface of the substrate to react with the epoxy groups of the glycidyl acrylate to covalently bond the PVP-containing copolymer to the substrate (Nagoacha et al., Biomaterials, 419 (1990)). Silicone rubber does not contain any free amino groups, and thus this type of coating cannot form covalent bonds with the surface of the sihcone substrate, resulting in poor adhesion.
  • PVP polyvinyl pyrrolidone-polyurethane interpolymer
  • PVP polyvinyl pyrrohdone
  • PVP linear preformed polyurethanes
  • PVP may be incorporated into a PU network by combining a polyisocyanate and a polyol with a PVP solution (U.S. Patents 5,160,790 and 5,290,585 to Elton).
  • Still another such coating is composed of two layers: a primer and a top coat.
  • the primer coat is a polyurethane prepolymer containing free isocyanate groups
  • the top coat is a hydrophilic copolymer of PVP and a polymer having active hydrogen groups, such as acrylamide (U.S. Patent 4,373,009 to Winn).
  • Hydrophilic polyurethanes have also been used in formulations other than with PVP as coatings for medical devices.
  • the prior art discloses coatings composed of polyurethane hydrogels containing a random mixture of polyisocyanates and a polyether dispersed in an aqueous liquid phase (U.S. Patent 4,118,354 to Harada et al.).
  • Polyurethanes have also been used as coatings in compositions containing chain-extended hydrophilic thermoplastic polyurethane polymers with a variety of hydrophilic high molecular weight non-urethane polymers (U.S. Patent 4,990,357 to Karkelle et al). It is also known to mix urethane with a silicone or siloxane emulsion.
  • the carboxylic acid groups of the substrate and coating may then be linked with a cross-linking agent, such as a polyfunctional aziridine (U.S. Patent 5,026,607 to Kiezulas).
  • urethane and non-urethane polymers cannot react with one another or the surface to be coated, the resulting coatings have poor adhesion, especially to sihcone surfaces. Also, since sihcone surfaces do not contain free carboxylic acid groups, a crosslinker such as a polyfunctional aziridine will not covalently bond known coatings to the surface of a sihcone substrate. Additionally, there are many instances in which is it convenient or desirable to provide an active agent to a surface by coating the surface with the active agent. For example, antimicrobial activity can be provided to the surface of an article by coating the article with an antimicrobial metal or an organic antimicrobial agent.
  • Alumino silicates or zeolites that contain ions of oligodynamic metals.
  • Aluminosilicates and zeolites contain exchangeable ions. These ions can be exchanged with ions of the desired antimicrobial metal from a salt of the metal.
  • coatings have been prepared by incorporating the antimicrobial agents described above into polymeric compositions.
  • metal ions and silicon dioxide have been coated on the surface of a silica gel that is used as a coating for medical devices.
  • metal ions have been incorporated into coatings of hydrophobic polymers.
  • Metal ions or salts have also been incorporated into polyurethane and other polymer coatings.
  • the present invention comprises biocompatible, hydrophilic silane copolymers, their manufacture, and their use as coatings for polydimethylsiloxane rubber and other difficult to coat substrates.
  • the coatings of the invention provide advantageous properties, such as improved durability, uniformity, and adhesion to sihcone and other surfaces which are difficult to coat, such as polyethylene and polypropylene.
  • the coatings of the present invention are beneficial because they retain lubricity and do not leach excessively over time.
  • the invention in a first aspect comprises a method for preparing a silane copolymer from one or more polyisocyanates; from one or more lubricious polymers having at least two functional groups, which may be the same or different, that are reactive with an isocyanate functional group; and from one or more organo- functional silanes having at least two functional groups, which may be the same or different, that are reactive with an isocyanate functional group and at least one functional group reactive with a silicone rubber substrate.
  • the invention also comprsises the silane copolymers made from the process described above.
  • the present invention comprises using the silane copolymers described herein to coat polysiloxane rubber and other difficult to coat substrates.
  • the coatings may comprise either a single layer or multiple layers.
  • the copolymers of the invention are employed as a primer coat over which a top coat is applied.
  • the coating is apphed as the sole coating to the catheter.
  • the copolymer coating incorporates additional components, including other hydrophilic polymers.
  • the present invention comprises silane copolymers that contain one or more active agents. The copolymer compositions can be used to coat substrate materials.
  • these coatings may comprise either a single layer or multiple layers.
  • the copolymer compositions of the present invention can be used alone or can be used in combination with other polymer coatings to provide advantageous properties to the surface of the substrate. These compositions can be used, for example, to prevent infection, to dehver pharmaceutical agents, or to inhibit algae, mollusk, or antimicrobial growth on surfaces.
  • the compositions of the invention can also be used as herbicides, insecticides, antifogging agents, diagnostic agents, screening agents, and antifoulants.
  • silane copolymer compositions and coatings containing these copolymers are provided.
  • compositions comprising a silane copolymer and an active agent.
  • compositions that provide antifogging properties. It is another object of the present invention to provide compositions that comprise a silane copolymer and an oligodynamic metal or metal salt.
  • compositions that comprise a silane copolymer and a zeohte containing ions of an oligodynamic metal.
  • compositions that comprise a silane copolymer and a biguanide.
  • compositions that comprise a silane copolymer and chlorhexidine or a salt of chlorhexidine.
  • compositions that comprise a silane copolymer and a colloids of oligodynamic salts.
  • compositions that comprise a silane copolymer and an antibiotic.
  • copolymer coatings of the present invention may take many different forms and may be made by many different methods, and that the disclosure of the preferred embodiments herein does not limit the scope of the invention. It should also be understood by those skilled in the arts that any active agent can be incorporated into the compositions of the present invention in the manner disclosed and that the disclosure of the preferred embodiments herein does not limit the scope of the invention.
  • the present invention comprises a process for preparing silane copolymers.
  • the invention in a first aspect comprises a method for preparing a silane copolymer from one or more polyisocyanates, from one or more lubricious polymers having at least two functional groups, which may be the same or different, that are reactive with an isocyanate functional group, and from one or more organo-functional silanes having at least two functional groups, which may be the same or different, that are reactive with an isocyanate functional group and at least one functional group reactive with a sihcone rubber substrate.
  • the silane copolymers of the present invention can be prepared by first forming a prepolymer from one or more of the polyisocyanates and one or more of the lubricious polymers followed by reaction with one or more of the organo-functional silanes.
  • the silane copolymers of the invention can be prepared by first forming a prepolymer from the polyisocyanate(s) and silane(s) followed by reaction with the lubricious polymer(s).
  • the silane copolymers of the invention can be prepared by simultaneously adding the polyisocyanate(s), lubricious polymer(s), and silane(s) and allowing them to react with one another to form the copolymer of the invention.
  • one or more polyols are reacted with an excess of one or more polyisocyanates in the presence of a catalyst, such as a tin catalyst.
  • a catalyst such as a tin catalyst.
  • the polyurethane product of this first step is then reacted with one or more amino-functional alkoxysilanes to form a polyurethane-urea-silane copolymer having pendant alkoxy groups.
  • This polyurethane-urea-silane copolymer is then optionally stabilized in solution by the addition of an alcohol, preferably the alcohol formed by the reaction of the alkoxy group with water.
  • one or more polyols are reacted with an excess of a diisocyanate in a first step to form an isocyanate-capped polyurethane prepolymer.
  • the formation of this prepolymer can be facilitated by employing an excess of polyisocyanate.
  • the number of isocyanate functional groups present in the reaction mixture is greater than the number of alcohol function groups present in the reaction mixture.
  • the ratio of isocyanate functional groups to alcohol or other isocyanate reactive functional groups is from 1.1:1 to 2:1. More preferably, the ratio of isocyanate functional groups to alcohol functional groups is from 1.5:1 to 2:1, most preferably 1.6 to 1.8.
  • the reaction between the polyol and polyisocyanate can also be facilitated by employing a catalyst.
  • suitable catalysts are tertiary amines, such as N,N-dimethylaminoethanol, N,N- dimethyl-cyclohexamine-bis(2-dimethyl aminoethyl) ether, N- ethylmorpholine, N,N,N',N',N"-pentamethyl-diethylene-triamine, and 1- 2(hydroxypropyl) imidazole, and metallic catalysts, such as tin, stannous octoate, dibutyl tin dilaurate, dioctyl tin dilaurate, dibutyl tin mercaptide, ferric acetylacetonate, lead octoate, and dibutyl tin diricinoleate.
  • the preferred catalyst is tin.
  • the most preferred catalyst is dioctyl tin dil
  • the isocyanate-capped polyurethane-urea prepolymer is reacted with an organo-functional silane to form a polyurethane-urea-silane copolymer having pendant alkoxy groups.
  • organo-functional silane having at least two functional groups, which may be the same or different, that are reactive with an isocyanate functional group, and at least one functional group reactive with a sihcone surface may be used in the process of the present invention.
  • the reaction can be facilitated by performing the polymerization in a dry organic solvent.
  • an optional third step comprises stabilization of the alkoxy groups of the polyurethane-urea-silane copolymer by the addition an alcohol of the alcohol corresponding to the reaction product of the alkoxy group with water.
  • one or more amino- functional alkoxysilanes are reacted with an excess of one or more polyisocyanates, preferably a diisocyanate.
  • the polyurea product of this first step is then combined with one or more polyols, optionally in the presence of a catalyst, such as a tin catalyst. If a catalyst is used, a polyurethane-urea-silane copolymer having pendant alkoxy groups. This polyurethane-urea-silane copolymer is then optionally stabilized in solution by addition of the alcohol corresponding to the alcohol formed by the reaction of the alkoxy group with water.
  • one or more amino-functional alkoxysilanes are reacted with one or more polyisocyanates, preferably a diisocyanate, and one or more polyols, optionally in the presence of a catalyst, such as a tin catalyst, to form a polyurethane-urea-silane copolymer having pendant alkoxy groups.
  • This polyurethane-urea-silane copolymer is then optionally stabilized in solution by addition of the alcohol corresponding to the alcohol formed by the reaction of the alkoxy group with water.
  • the resulting polyurethane-urea-silane copolymers contain numerous free alkoxy groups which react with the sihcone surface but can also react with any water present in the reaction system.
  • the reaction of the alkoxy groups with water cleaves alcohol from the copolymer and leaves silanol groups in place of the alkoxy groups.
  • These silanols may react with the sihcone substrate or with each other, the latter producing crosslinks in the copolymer which can affect coating properties.
  • Addition to the copolymer solution of the alcohol formed by the reaction of the alkoxy group contained in the copolymer and water helps to stabilize the copolymer by inhibiting the reaction of alkoxy groups with water.
  • examples of such alcohols include, but are not limited to, methanol, ethanol, 1-propanol, 2-propanol, butanol, hexanol and octanol.
  • the particular alcohol used will depend upon the alkyl portion of the alkoxy group. For example, methanol is used to stabilize a copolymer containing methoxy groups.
  • the alcohol is generally added at the end of polymerization in an amount from 5 to 50% of the total solvent composition, preferably from 10 to 30%.
  • Any polyol may be used in the process of the invention and is preferably dried to less than 1000 ppm water before reaction.
  • examples of such polyols include, but are not limited to, polyethylene glycols, polyester polyols, polyether polyols, caster oil polyols, and polyacrylate polyols, including Desmophen A450, Desmophen A365, and Desmophen A 160 (Mobay Corporation, Pittsburgh, PA).
  • the process advantageously employs a diol as the polyol.
  • Suitable diols include, but are not limited to, poly(ethylene adipates), poly(diethyleneglycol adipates), polycaprolactone diols, polycaprolactone- polyadipate copolymer diols, poly(ethylene-terephthalate)diols, polycarbonate diols, polytetramethylene ether glycol, polyethylene glycol, ethylene oxide adducts of polyoxypropylene diols, ethylene oxide adducts of polyoxypropylene triols.
  • the preferred polyol is the diol polyethylene glycol.
  • the most preferred polyethylene glycol is Carbowax 1450TM
  • amine functional polymers may be used in the process of the invention to produce isocyanate-functionahzed polyureas for reaction with an amino-functional alkoxysilane.
  • amine functional chain extenders common to the art of polyurethane synthesis and water which also produces polyureas by reaction with isocyanates to produce amines, may also be employed. Monomers containing such chain extenders also produce polyureas.
  • Any polyisocyanate may be used in the process of the present invention.
  • the polyisocyanate may be aromatic, ahphatic or cycloaliphatic.
  • Nonhmiting examples of such polyisocyanates are 4,4'- diphenylmethane diisocyanate and position isomers thereof, 2,4- and 2,6- toluene diisocyanate (TDI) and position isomers thereof, 3,4- dichlorophenyl diisocyanate, dicyclohexylmethane-4,4'-diisocyanate (HMDI), 4,4'-diphenylmethane diisocyanate (MDI), 1,6-hexamethylene diisocyanate (HDI) and position isomers thereof, isophorone diisocyanate
  • IPDI adducts of diisocyanates, such as the adduct of trimethylolpropane and diphenylmethane diisocyanate or toluene diisocyanate.
  • the preferred polyisocyanate is the diisocyanate dicyclohexylmethane-4,4'-dhsocyanate (HMDI).
  • organo-functional silanes having at least two functional groups, which may be the same or different, that are reactive with an isocyanate functional group and at least one functional group reactive with a sihcone surface may be used in the process of the present invention.
  • organo-functional silanes are N-beta- (aminoethyl)-gamma-aminopropyl-trimethoxy silane and N-(2-aminoethyl)-
  • the preferred organo-functional silane is a diamino-alkoxysilane, such as N-(2-aminoethyl)-3- aminopropylmethyldimethoxy silane.
  • a catalyst to the isocyanate reaction mixtures.
  • the preferred catalyst for the present invention is any tertiary amine or metallic catalyst.
  • suitable catalysts include tertiary amines, such as N,N-dimethylaminoethanol, N,N- dimethyl-cyclohexamine-bis(2-dimethyl aminoethyl) ether, N- ethylmorpholine, N,N,N',N',N"-pentamethyl-diethylene-triamine, and 1-
  • 2(hydroxypropyl) imidazole and metallic catalysts, such as tin, stannous octoate, dibutyl tin dilaurate, dioctyl tin dilaurate, dibutyl tin mercaptide, ferric acetylacetonate, lead octoate, and dibutyl tin diricinoleate.
  • the preferred catalyst is tin with the most preferred being dioctyl tin dilaurate.
  • a solvent is advantageously added to the prepolymer or monomer mixture to reduce viscosity. The level of viscosity is important during the synthesis of the copolymers of the present invention. During polymerization, if the copolymer solution attains too high a viscosity, the solution can form a gel from which good quality coatings cannot be made.
  • the coating formed will be too thick to produce a uniform thin coating on the substrate. Such a coating may also have low durability due to cracking. On the other hand, if copolymer solution has too low a viscosity, the coating formed will exhibit poor and uneven adhesion.
  • Viscosity is a function of molecular weight of the copolymer and the solids content of the solution and is controUed by addition of solvent to the solution.
  • the preferred copolymer solution for dip coating has a kinematic viscosity in a range of about 1.5 to 20 cS (centistokes), preferably 2.0 to 10 cS, and most preferably 2.5 to 5 cS.
  • the preferred copolymer solution has a sohds content in a range of about 0.4 to 5%, most preferably from 0.6 to 1.5%.
  • the solvent be dry to prevent water contamination of the prepolymer because water may react with alkoxy groups of the silane.
  • the solvent preferably contains less than
  • Solvents which are useful in the present invention include, but are not hmited to, tetrahydrofuran, acetonitrile, ethyl acetate, methylene chloride, dibromomethane, chloroform, dichloroethane, and dichloroethylene, with tetrahydrofuran being preferred.
  • the present invention comprises the silane copolymers made by the processes described above.
  • These copolymers are preferably polyurethane-urea-silane copolymers.
  • Particularly preferred copolymers are polyurethane-urea-silane copolymers having from 7 to 12% by weight silane based upon the weight of the entire copolymer.
  • the most preferred copolymers of the invention are those comprised of dicyclohexylmethane-4,4'-diisocyanate, N-(2-aminoethyl)-3- aminopropylmethyl-dimethoxy silane, and Carbowax 1450TM.
  • the silane copolymers can contain additional components. For example, they may contain viscosity and flow control agents, antioxidants, conventional pigments, air release agents or defoamers, and other hydrophilic polymers.
  • Antioxidants are not necessary, but may be used to improve the oxidative stability of the coatings.
  • Nonhmiting examples of useful antioxidants are vitamin E, tris(3,5-di-t-butyl-4-hydroxy benzyl)isocyanurate, 2,2'-methylenebis(4-methyl-6-t-butyl phenol), 1,3,5- trimethyl-2,4,6-tris(3,5-di-t-butyl-4-hydroxy benzyl) benzene, butyl- hydroxytoluene, octadecyl-3,5-di-t-butyl-4-hydroxy hydrocinnamate, 4,4'- methylenebis(2,6-di-t-butylphenol), p,p'-dioctyl-diphenylamine, and 1 , 1 ,3-tris-(2-methyl-4-hydroxy-5-t-butylphenyl) butane.
  • Conventional dyes and pigments can be added to impart color or radiopacity or to enhance the aesthetic appearance of the coatings produced from the copolymers.
  • the present invention comprises a method for using the silane copolymers described above to form wet lubricious coatings on substrates.
  • the copolymers can be used to coat any substrate, but are particularly useful for coating difficult to coat substrates.
  • the preferred substrate is a polysiloxane rubber
  • the copolymer is also useful for coating other difficult to coat substrates, such as polyethylene and polypropylene, as well as other polymers, glass, metal, and ceramics.
  • Many medical devices such as guide wires; catheters, including Foley, angioplasty, diagnostic, and balloon catheters; implant devices; contact lenses; IUDs; peristaltic pump chambers; endotracheal tubes; gastroenteric feed tubes; arteriovenous shunts; condoms; and oxygenator and kidney membranes, are made from silicone rubber and these other substrates.
  • the silane copolymers of the invention may be apphed to the substrate by conventional methods known in the art.
  • the substrate is dipped into a solution of the copolymer of the present invention.
  • the substrate is dipped into the copolymer solution at a rate of about 15-80 inches per minute (ipm), preferably about 40 ipm.
  • the substrate is preferably allowed to remain in the coating solution for 0- 30 seconds, preferably about 5-15 seconds, and then is withdrawn at a rate of about 10-80 ipm, preferably 15-30 ipm.
  • the substrate Once the substrate has been coated with the copolymer of the invention, it is allowed to air dry for at least 1 hour.
  • the substrate may optionally be dried with a hot air stream or in an oven at a temperature of approximately 50 to 100°C for about 5-60 minutes to remove residual solvent.
  • the silane copolymers of the present invention can be used to form a variety of unique coatings by varying the exact components incorporated into the copolymer. Some of the copolymers are both very lubricious when wet and adhesive to the substrate. These copolymers can be used as the sole coating on the substrate. Other of the copolymers of the invention are less lubricious but have superior adhesion. These copolymers can be used as a primer coat over which a lubricious top coat may be attached.
  • the silane copolymer of the invention may be apphed to the substrate as a primer coat over which a second lubricious top coat is then applied.
  • the silane copolymer acts as a primer, facilitating adhesion of the second top coat to the substrate.
  • the top coat may be apphed by any method, but is advantageously apphed by dipping the primed substrate into a solution of the top coat in a manner similar to that by which the primer is apphed.
  • the invention is further described in terms of two coating layers, a primer coat and a top coat, it is to be understood that many coating layers can be employed in the present invention. These coating layers are formed in the same manner as the primer and top coat.
  • the preferred polyol used in the preparation of the silane copolymer is polyethylene glycol (PEG).
  • PEG is a polymeric diol which is available in a variety of molecular weights. The use of PEG having different molecular weights affects the molecular weight and the wet lubricity of the coatings formed.
  • a PEG having a lower molecular weight is employed. Lower molecular weigh PEGs are those having a molecular weight of less than approximately 6,000 Daltons, such as Carbowax
  • Carbowax 1450TM provides a prepolymer having a molecular weight that is generally between about 1,900 and 25,000 as measure by gel permeation chromatography (GPC).
  • GPC gel permeation chromatography
  • a copolymer made from such a prepolymer provides improved adhesion of the primer coat to the substrate.
  • the lubricious top coat may be any coating which enhances the lubricity of the substrate.
  • One preferred top coat is the combination of a higher molecular weight polyethylene oxide, such as Hydro slide 121 (C.R. Bard, Inc., Murray Hill, N.J.) or a polyvinyl pyrrolidone and a reactive mixture of polyfunctional isocyanate and polyol. Examples of such top coats include the coatings disclosed in U.S. Patents No. 5,077,352; 5,179,174; 5,160,790; and 5,209,585, herein incorporated by reference.
  • the lubricious top coat that is apphed over the primer coat is the silane copolymer of the present invention made with a higher molecular weight PEG.
  • Higher molecular weight PEGs are those having a molecular weight between approximately 7,000 Daltons and approximately 20,000 Daltons, such as Carbowax 8000TM.
  • the silane copolymers of the invention may be apphed to the substrate as a single coating when a sufficiently lubricious polyol, such as Carbowax 8000TM, is incorporated into the copolymer.
  • the copolymers of the invention may be used alone as the single coating, or may incorporate additional hydrophilic polymers into the copolymer to add desirable properties to the coating.
  • the preferred copolymers of this embodiment contain at least one additional hydrophilic polymer, such as polyethylene glycol (PEG), polyethylene oxide (PEO), or polyvinyl pyrrolidone (PVP).
  • Hydrophilic polymers that may be added to the copolymer solution include, but are not limited to, polyethylene oxide (PEO), polyethylene glycol (PEG), polysaccharides, hyaluronic acid and its salts and derivatives, sodium alginate, chondroitin sulfate, celluloses, chitin, chitosan, agarose, xanthans, dermatan sulfate, keratin sulfate, emulsan, gellan, curdlan, amylose, carrageenans, amylopectin, dextrans, glycogen, starch, heparin sulfate, and limit dextrins and fragments thereof; synthetic hydrophilic polymers, poly(vinyl alcohol), and poly(N-vinyl) pyrrolidone (PVP).
  • the preferred hydrophilic polymer for use in the present invention is polyethylene glycol.
  • the lubricious coatings made by this process have a number of advantageous properties. These properties include a reduced coefficient of friction when wet, providing a very slippery surface, increased coating adhesion to sihcone and other difficult to coat substrates, and increased coating durability on such substrates.
  • Coefficient of friction is a measure of how slippery the coating is when contacted with another surface, such as body tissue. The lower the COF, the more slippery is the coating. Medical devices whose surfaces become slippery when wet decrease patient discomfort and decrease trauma to the patient's tissue. It is, therefore, desirable to produce a coating having as low of a COF as possible when wet.
  • the coatings of the present invention have a COF when wet of between 0.01 and 0.2, preferably between 0.01 and 0.12, and more preferably between 0.01 and
  • coatings of the present invention are excellent for use on the surface of medical devices, especially those made of silicone and other difficult to coat surfaces because they reduce the COF of the surfaces.
  • Coating adhesion and durability are both affected by the copolymer' s molecular weight.
  • the molecular weight in turn is dependent upon a number of factors: (1) the amount of water initially present in the polyol, (2) the final prepolymer molecular weight, (3) the prepolymer isocyanate functionality, (4) how close the ratio of prepolymer isocyanate groups to amine groups in the organo-functional silane approaches a 1:1 stoichiometric ratio, (5) purity of the silane monomer, (6) the water content of the solvents used, and (7) the degree of viscosity the copolymer is allowed to attain before the final dilution.
  • the ratio of isocyanate groups on the prepolymer to amine groups on the organo-functional silane also affects the molecular weight of the copolymer.
  • a 1:1 ratio produces a copolymer approaching infinite molecular weight.
  • the number of free isocyanate groups present in the prepolymer limits the number of sites available for reaction with the amine groups on the organo-functional silane.
  • the purity of the silane affects the number of amine groups available for reaction.
  • the silane copolymers of the present invention can contain one or more active agents, which are either retained in the composition or released from the composition, preferably over time.
  • active agents include antimicrobial agents, such as antibacterial agents, antifungal agents, antiviral agents and antibiotics; growth factors; cytokines; immunoglobulins; pharmaceuticals and nutraceuticals, including, but not limited to, antithrombogenic agents, antitumoral agents, antiangiogenic agents, spermicides, anesthetics, analgesics, vasodilation substances, wound healing agents, plant extracts, and other therapeutic and diagnostic agents.
  • Other active agents useful in the present invention include herbicides, insecticides, algaecides, antifoulants, antifogging agents, and UV and other screening agents. Of these agents, those which can be used for medical applications are preferred.
  • the active agent is advantageously present in the composition in amounts from about 0.1% to about 50% of the dry weight of the composition. Preferred amounts of the active agent are 1% to 30% of the composition based upon the dry weight of the composition .
  • agents have antimicrobial, antibacterial, antiviral, or antifungal activity and are examples of the types of agents that can be used in the present invention. It will be understood by one of ordinary skill in the art that these are nonhmiting examples and that other active agents can be incorporated into the copolymers of the present invention in a manner similar to the incorporation of the specifically recited agents.
  • the active agent is one or more oligodynamic metals or salts of oligodynamic metals.
  • Oligodynamic metals include, but are not limited to, silver, gold, zinc, copper, cesium, platinum, cerium, gallium, and osmium.
  • Suitable salts of such metals include, but are not limited to, acetates, ascorbates, benzoates, bitartrates, bromides, carbonates, chlorides, citrates, folates, gluconates, iodates, iodides, lactates, laurates, oxalates, oxides, palmitates, perborates, phenosulfonates, phosphates, propionates, salicylates, stearates, succinates, sulfadiazines, sulfates, sulfides, sulfonates, tartrates, thiocyanates, thioglycolates, and thiosulfates.
  • ohgodynamic metals and metal salts can be used alone, or in combination with other ingredients.
  • ingredients include salts that enhance the activity of the oligodynamic metal, substances that promote the galvanic activity of the ohgodynamic metal, agents which enhance or inhibit release of the ohgodynamic metal from the composition, or other active agents.
  • the active agent comprises zeohtes in which some or all of the exchangeable-ions have been replaced with an ohgodynamic metal.
  • the zeohte can be any aluminosilicate, zeolite, or mordenite having ions that can be exchanged with an oligodynamic metal.
  • Nonhmiting examples of such zeohtes include, but are not limited to, zeohte A, zeohte Y, zeohte X, ZSM-4, ZSM-5, ZSM-11, zeolite- ⁇ , and mordenites.
  • the zeohte can be exchanged with any oligodynamic metal, such as those listed above, by conventional methods known in the art.
  • the zeohte can be exchanged with other ions that enhance the activity of the antimicrobial zeohte or that provide additional beneficial properties, such as inhibiting discoloration of the zeohte containing composition or affect the release or rate of release of the ohgodynamic metal.
  • the active agent comprises colloids of ohgodynamic metal salts.
  • Colloids that can be employed in the present invention, for example, are those described in commonly assigned U.S . Patent Apphcation Serial No. 09/461,846, filed December 15, 1999, the entire disclosure of which is incorporated by reference herein.
  • the colloid comprises one or more ohgodynamic metal salts.
  • the ohgodynamic salts comprise one or more salts of ohgodynamic metals.
  • the salts may be different salts of the same ohgodynamic metal or may be salts of different oligodynamic metals.
  • Ohgodynamic metals useful in the present invention include, but are not limited to, silver, platinum, gold, zinc, copper, cerium, gallium, osmium, and the like.
  • the preferred ohgodynamic metal is silver. Salts of other metals may be employed to form the colloid.
  • These salts contain cationic ions that include, but are not limited to, calcium, sodium, lithium, aluminum, magnesium, potassium, manganese, and the like, and may also include ohgodynamic metal cations such as copper, zinc, and the like.
  • These salts contain anions that include, but are not limited to, acetates, ascorbates, benzoates, bitartrates, bromides, carbonates, chlorides, citrates, folates, gluconates, iodates, iodides, lactates, laurates, oxalates, oxides, palmitates, perborates, phenosulfonates, phosphates, propionates, salicylates, stearates, succinates, sulfadiazines, sulfates, sulfides, sulfonates, tartrates, thiocyanates, thioglycolates, thiosulfates, and the like.
  • compositions of the present invention can also contain additional components.
  • the compositions can contain salts of metals that enhance the antimicrobial effect of the ohgodynamic metal, such as the platinum group metals, or other metals that promote galvanic action.
  • composition can include agents that affect the release of the ohgodynamic metal.
  • the active agent comprises biguanides, preferably chlorhexidine or chlorhexidine salts.
  • Preferred salts include the acetate, formate, gluconate, hydrochloride, isoethionate, lactate, and succinamate of chlorhexidine.
  • These biguanide compounds are known in the art and can be prepared by conventional methods. Numerous other biguanides are known and contemplated for use by the present invention. Biguanides can also form polymers. Use of these biguanide polymers is also contemplated by the present invention.
  • the active agent comprises typical antimicrobial agents, growth factors, cytokines, immunoglobuhns, or pharmaceuticals and nutriceuticals.
  • Typical antibiotics that are also useful in the present invention include, but are not limited to, amoxicilhn, amphotericin, ampicillin, bacitracin, beclomethasone, benzocaine, betamethasone, biaxin, cephalosporins, chloramphenicol, ciprofloxacin, clotrimazole, cyclosporin, docycline, enoxacin, erythromycin, gentamycin, miconazole, neomycin, norfloxacin, nystatin, ofloxacin, pefloxacin, peniciUin, pentoxifylline, phenoxymethylpenicillin, polymixin, rifampicin, tetracycline, tobrmycin, triclosan, vancomycin, zithromax, derivatives, metabolites, and mixtures
  • Growth factors useful in the present invention include, but are not limited to, transforming growth factor- ⁇ ("TGF- ⁇ ”), transforming growth factor- ⁇ ("TGF- ⁇ ”), vascular epithelial growth factor ("VEGF”), basic fibroblast growth factor, insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF) and mixtures thereof.
  • Cytokines useful in the present invention include, but are not hmited to, IL-1, IL-2, IL-3, IL- 4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF- ⁇ , and
  • Immunoglobulins useful in the present invention include, but are not limited to, IgG, IgA, IgM, IgD, IgE, and mixtures thereof.
  • Pharmaceutical agents useful in the present invention include, but are not hmited to, antibacterial agents, antithrombogenic agents, antiinflammatory agents, antitumoral agents, antiangiogenic agents, spermicides, anesthetics, analgesics, vasodilation substances, wound healing agents, other therapeutic and diagnostic agents, and mixtures of these.
  • Some specific examples of pharmaceutical agents that are useful as active agents include, but are not limited to, quinolones, such as oxohnic acid, norfloxacin, and nalidixic acid, sulfonamides, nonoxynol 9, fusidic acid, cephalosporins, acebutolol, acetylcysteine, acetylsahcyhc acid, acyclovir, AZT, alprazolam, alfacalcidol, allantoin, allopurinol, ambroxol, amikacin, amiloride, aminoacetic acid, aminodarone, amitriptyline, amlodipine, ascorbic acid, aspartame, astemizole, atenolol, benserazide, benzalkonium hydrochloride, benzoic acid, bezafibrate, biotin, biperiden, bisoprolol, bromazepam, bro
  • the active agent comprises one or more herbicide, insecticide, algaecide, antifoulant, antifogging agent, or UV or other screening agent.
  • compositions of the present invention can contain any combination of these or other active agents.
  • the compositions can also contain additional components such as colorants, discoloration inhibitors, agents that affect the release or rate of release of the active agent, surfactants, adhesion agents, agents that enhance the activity of the active agent, solubihzing agents, agents that enhance the lubricity of the compositions, and other agents which provide beneficial properties to the compositions.
  • the active agent can be incorporated into the compositions of the present invention by any suitable method.
  • the active agent can be mixed with the components of the copolymer composition in a solvent suitable for both the copolymer and the active agent.
  • solvents include, but are not limited to, those discussed above in the process for making the copolymer without the active agent.
  • the active agents can be mixed with the monomers that form the copolymer prior to polymerization, provided that the active agent will not be deactivated by polymerization conditions.
  • the monomeric components are then polymerized as described above or by methods known in the art.
  • the copolymer is formed as described above, followed by addition of the active agent to the copolymer solution.
  • the active agent is a colloid of ohgodynamic metal salts
  • the composition can also be prepared via the method disclosed in commonly assigned copending Apphcation Serial No.
  • the copolymer compositions of the present invention can be coated onto the surface of an article.
  • Preferred articles are medical devices. The same is true when the composition comprises one or more active agents.
  • the device can first be coated with a layer of silver as described in U.S. Patents No. 5,395,651; 5,747,178; and 5,320,908 to Sodervall et al, the disclosures of which are incorporated by reference herein.
  • the copolymer composition of the present invention can then be coated over the silver coated catheter in a manner as described above.
  • compositions of the invention comprising the active agent can be used in combination with one or more additional coating compositions to coat the surface of a device.
  • this embodiment comprises the use of two compositions to provide two distinct coatings on the device. It should be understood that the invention can also be practiced with multiples layers following the same principles as described below.
  • coatings may contain the same polymeric composition or different polymeric compositions, so long as one of the coatings comprises a silane copolymer of the present invention.
  • coating layer closest to the substrate surface it is convenient to refer to the coating layer closest to the substrate surface as a primer or base coat and to the coating layer most exterior as the top coat.
  • compositions of the present invention can be employed as either the base coat, the top coat, or both. They can also be employed as intermediate coating layers when used with other coatings of the present invention or known in the art.
  • exact formulation of the compositions of the present invention vary depending upon whether the composition is employed as a base coat or top coat. These variations are described above. Additionally, conventional compositions can be employed as either a base coat or a top coat in conjunction with the compositions of the present invention.
  • the base coat comprises a polymeric composition that improves adherence of the other coating layers to the substrate.
  • the silane copolymers of the present invention comprised of low molecular weight polyethyl glycols are particularly suitable for use as a base coat. These copolymers comprise a PEG having a molecular weight below approximately 6,000 Daltons, preferably
  • top coats that provide a dry elastic coating that becomes lubricious when wet.
  • the silane copolymers of the present invention comprised of high molecular weight polyethylene glycols are particularly suitable for use as a top coat. These copolymers comprise a PEG having a molecular weight of approximately 7,000 Dalton to approximately 20,000 Daltons, preferably Carbowax 8000TM. Also particularly suitable for use as a top coat is Hydroslide 121 polyurethane.
  • any of the coating layers can comprise one or more active agents. Where multiple coatings contain an active agent, the active agents in the coatings may be the same or different. Further, one or more of the coatings can contain additional agents that provide advantageous properties to the device. For example, any of the coatings, regardless of whether it contains an active agent, can also contain agents that affect the release or rate of release of the active agent. The coatings can also contain agents that improve adhesion of the coatings to the substrate or to the base coat, improve wet lubricity of the surface, inhibit discoloration of the compositions containing active agents that discolor, provide additional therapeutic activity, enhance the activity of the active agent, provide galvanic action for active agents containing an ohgodynamic metal, and the like.
  • the particular polymeric compositions of the coatings can be designed to provide some of the properties hsted above, such as improved adhesion, improved lubricity, or to enhance or inhibit release of the active agent.
  • the preferred substrates are medical devices.
  • medical devices include, for example, catheters, guidewires, implant devices, contact lenses, IUDs, peristaltic pump chambers, endotracheal tubes, gastroenteric feed tubes, arteriovenous shunts, condoms, and oxygenator and kidney membranes.
  • Use of particular active agents in the various coating layers provides particular beneficial effects. For example, use of antibiotics or antimicrobials, inhibits the adhesion of bacteria to the surface of the device and can prevent infection in the surrounding tissue.
  • compositions of the present invention can also be used as dehvery agents to provide beneficial agents to patients, for example, antimicrobials, growth factors, cytokines, immunoglobulins, or other pharmaceutical agents, such as antitumor agents, antithrombogenics, and the like.
  • beneficial agents for example, antimicrobials, growth factors, cytokines, immunoglobulins, or other pharmaceutical agents, such as antitumor agents, antithrombogenics, and the like.
  • the compositions of the present invention can be used as coatings on substrates, such as medical devices, bandages, or devices known in the art for topical dehvery of pharmaceutical agents.
  • compositions of the present invention can be incorporated with other inert or topical dehvery components to provide topical compositions.
  • These compositions can be, for example, in the form of lotions, ointments, salves, creams, or transdermal dehvery compositions, such as patches.
  • These compositions can be apphed to the skin or mucosal membranes by methods known in the art to provide topical dehvery of the active agents.
  • compositions of the present invention can also be used to coat glass beads, chromatography packing material, and other substances for use as diagnostic agents. It is contemplated that the active agents incorporated in such compositions are those that can detect the desired chemical or substance to be detected. Detection of the appropriate substance can be performed by convention methods, such as ELISA assays, radioimmunoassays, NMR, fluorescent spectroscopy, and the like.
  • the compositions of the present invention can also be used to coat consumer products and other surfaces to provide an active agent on the surface. While it is preferred to dip coat medical devices, such as catheters and stents, the compositions of the present invention can also be sprayed or brush coated for applications where dip coating is not feasible.
  • copolymer compositions of the present invention are useful include coating the compositons onto pools, spas, ships, and the like to provide algaecidic activity, antifoulant activity, or both.
  • the coatings of the invention can be apphed to ship hulls to prevent attachment of mollusks, or to pool liners to prevent bioslime.
  • compositions of the invention containing the active agents disclosed herein can be ascertained by those of skill in the art in light of the present disclosure.
  • PEG Polyethylene glycol
  • Union Carbide Union Carbide
  • 50 g molecular sieves The jar was then placed in a vacuum oven at 68°C for 72 hours under full vacuum. The water content of the PEG was then analyzed by
  • a three neck 300 ml round bottom flask was equipped with an overhead stirrer, a nitrogen inlet, and a nitrogen bubbler.
  • the flask was placed in a 70°C oil bath.
  • the nitrogen bubbler was removed and 11.60 g dried, molten PEG 1450 was injected into the flask with a syringe.
  • To the molten PEG was added 4.03 g of Desmodur W (Bayer, Inc. Germany) by syringe.
  • the flask was then flushed with nitrogen, and a nitrogen blanket was maintained over the reaction mixture throughout the procedure.
  • reaction mixture was stirred until homogenous.
  • 0.015 g of dioctyl tin dilaurate was added to the reaction mixture with a syringe.
  • the mixture was then stirred for 1.2 hours at 68°C to form the urethane prepolymer.
  • a three-neck, 500 ml, round bottom flask was set up with an overhead stirrer, addition funnel with nitrogen inlet, and septum seal with nitrogen bubbler (outlet). The system was flushed with nitrogen. 111.5 g of dry (less than 100 ppm water) tetrahydrofuran (THF) was added to the urethane prepolymer prepared in Example 2, and the mixture was stirred until homogenous.
  • dry (less than 100 ppm water) tetrahydrofuran (THF) was added to the urethane prepolymer prepared in Example 2, and the mixture was stirred until homogenous.
  • N-(2-aminoethyl)-3-aminopropyl- methyldimethoxy silane (DAS) (Gelest, Inc.) was dissolved in 38.63 g THF and added continuously to the prepolymer solution via the addition funnel over a period of approximately five minutes to begin the polymerization.
  • the solids concentration of the solution was approximately 10% at this point.
  • the viscosity of the mixture was monitored, and when it increased to 70.9 centipoise (cP), 48.3 g of anhydrous THF was added. The viscosity fell and then began building again. When it reached 70.0 cP again, 49.33 g of anhydrous THF was added. This process was repeated, adding another 48.62 g of anhydrous THF when 67.6 cP was reached. When the viscosity reached the fourth target of 66.0 cP, 30.16g of THF was added to produce a 5% solids solution. When the viscosity reached a final viscosity of 67.1 cP, the solution was transferred into a 2 L vessel containing 690 g of THF and stirred until homogeneous.
  • cP centipoise
  • Desmodur CB60N (Bayer, Inc., Germany) was added to the solution and mixed until homogenous.
  • Example 5 Thirty catheters were dipped into the primer copolymer solution of Example 3 at a rate of about 41.2 ipm. The catheters were allowed to remain in the coating solution for 10 seconds and then withdrawn at a rate of about 14.9 ipm. The catheters were air dried by passing a gentle stream of air through the drainage lumen of the catheters for about 5 minutes, followed by air drying for one hour.
  • Example 5 The thirty catheters from Example 5 were then dipped into a solution of the Hydroslide 121 coating prepared in Example 4 at a rate of 41.1 ipm and withdrawn at a rate of 15.2 ipm.
  • the catheters were then air dried by passing a gentle stream of air through the drainage lumen for about 5 minutes, air drying them for an additional 30 minutes, and then placing them into an oven at 80 °C for 15 minutes.
  • the catheters were allowed to cool and then packaged and sterilized with ethylene oxide (ETO). After sterilization, the coefficient of friction of 10 pairs of the silicone copolymer coated catheters was evaluated over a 21 day period in which the catheters were incubated in water at 37°C. When compared with the coefficient of friction of uncoated silicone catheters, the results confirmed a highly lubricious, durable hydrophilic coating on the sihcone catheters.
  • ETO ethylene oxide
  • Example 7 Preperation of silicone Foley catheter having an antimicrobial primer and a wet lubricious top coat.
  • a polurethane-urea-silane copolymer primer solution was prepared as described in Example 3.
  • a 5% solution of chlorhexidine diacetate in a 75:25 mixture of methanol and tetrahydrofuran was prepared, and 3.24 g of this solution was combined with 400 g of the primer solution to produce a primer solution containing 5% chlorhexidine based on dry weight.
  • Thirty silicone Foley catheters were then dipped into the 5% chlorhexidine/primer solution as described in Example 5, Hydroslide 121 was then applied as a top coat in the manner described in Example 6.
  • a polurethane-urea-silane copolymer primer solution was prepared as described in Example 3.
  • a Hydroslide 121 wet lubricious top coat was prepared as described in Example 4.
  • a 5% solution of chlorhexidine diacetate in methanol was prepared, and 3.93 g of this solution was combined with 400 g of the Hydroslide 121 solution to produce a top coat solution containing 5% chlorhexidine based on dry weight.
  • Thirty sihcone Foley catheters were dipped into the primer solution and dried as described in Example 5. The catheters were then top coated with Hydroslide 121 containing 5% chlorhexidine as described in Example 6.
  • Example 9 Preperation of sihcone Foley catheter having a silver antimicrobial primer and a wet lubricious top coat.
  • a polurethane-urea-silane copolymer primer solution was prepared as described in Example 3.
  • a 10% solution of silver nitrate in 50:50 methano water was prepared, and 3.60 g of this solution was combined with 400 g of the primer solution to produce a primer solution containing 10% silver nitrate based on dry weight.
  • a 2% solution of sodium chloride in water was prepared, and 3.10 g of this NaCl solution was added slowly to the silver nitrate/primer solution to produce a fine colloid of silver chloride from half of the silver nitrate.
  • Thirty sihcone Foley catheters were then dipped into the silver loaded primer solution as described in Example 5, followed by top coating with Hydroslide 121 as described in Example 6.
  • Example 10 Preperation of sihcone Foley catheter having a silver antimicrobial primer and an antimicrobial wet lubricious top coat.
  • a silver colloid containing primer solution was prepared as described in Example 9.
  • a chlorhexidine containing top coat solution was prepared as described in Example 8.
  • Thirty sihcone Foley catheters were dipped into the silver/primer solution and dried as described in Example 5. The catheters were then top coated with Hydroslide 121 containing 5% chlorhexidine as described in Example 6.

Abstract

La présente invention concerne des copolymères de silane préparés par réaction d'un ou de plusieurs polyisocyanates avec un ou plusieurs polymères à pouvoir lubrifiant présentant au moins deux groupes fonctionnels, identiques ou différents, étant réactifs avec un groupe fonctionnel d'isocyanante et avec un ou plusieurs silanes organo-fonctionnels présentant au moins deux groupes fonctionnels, identiques ou différents, étant réactifs avec un groupe fonctionnel d'isocyanate et au moins un groupe fonctionnel réactif avec un substrat en caoutchouc de silicone. Les copolymères de silane selon l'invention peuvent être utilisés en tant que revêtements dotés de propriétés élastiques à l'état sec, de propriétés lubrifiantes à l'état mouillé et résistants à l'abrasion à l'état humide. Ces copolymères sont utiles en tant que revêtements destinés au polysiloxane (caoutchouc) et à d'autres substrats difficiles à revêtir, notamment pour des dispositifs médicaux, tels que des cathéters. Ces copolymères de silane peuvent renfermer des principes actifs tels que des agents antimicrobiens, pharmaceutiques, herbicides, insecticides, algicides, antisalissures et anticondensation.
EP00930553A 1999-11-05 2000-05-10 Compositions copolymeres de silane renfermant des principes actifs Withdrawn EP1228146A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1999/026155 WO2000027897A2 (fr) 1998-11-10 1999-11-05 Revetements en copolymere au silane
WOPCT/US99/26155 1999-11-10
PCT/US2000/012789 WO2001053414A1 (fr) 1998-11-10 2000-05-10 Compositions copolymeres de silane renfermant des principes actifs

Publications (1)

Publication Number Publication Date
EP1228146A1 true EP1228146A1 (fr) 2002-08-07

Family

ID=22273994

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00930553A Withdrawn EP1228146A1 (fr) 1999-11-05 2000-05-10 Compositions copolymeres de silane renfermant des principes actifs

Country Status (4)

Country Link
EP (1) EP1228146A1 (fr)
JP (1) JP4667698B2 (fr)
AU (1) AU4835300A (fr)
MX (1) MXPA02004673A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109661382A (zh) * 2016-09-20 2019-04-19 Usg内部有限责任公司 用于改善吸音板性能的硅酸盐涂料及其制备方法
CN114767944A (zh) * 2022-03-14 2022-07-22 四川大学华西医院 具备超亲水能力的抗菌抗凝涂层材料及其制备方法与应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530932T1 (de) * 2007-01-31 2011-11-15 Novartis Ag Antimikrobielle medizinische vorrichtungen mit silbernanopartikeln
JP5023802B2 (ja) * 2007-05-15 2012-09-12 株式会社カネカ 医療用バルーンとステントデリバリーシステム及びその製造方法
EP2177238B1 (fr) * 2008-10-14 2016-11-09 Dentsply IH AB Dispositif médical doté d'un agent antibactérien dont la libération peut être contrôlée
JP5669035B2 (ja) * 2009-11-24 2015-02-12 株式会社 ティーアールエス 潤滑性表面を有する医療用具
US8287890B2 (en) * 2009-12-15 2012-10-16 C.R. Bard, Inc. Hydrophilic coating
US20110301553A1 (en) * 2010-06-04 2011-12-08 Smiths Medical Asd, Inc. Antimicrobial lubricant
KR101602402B1 (ko) * 2014-04-29 2016-03-10 주식회사 엠아이텍 스텐트
JP7311141B2 (ja) * 2019-07-10 2023-07-19 日東化成株式会社 防汚塗料組成物、該組成物を用いて形成される防汚塗膜を表面に有する塗装物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59228856A (ja) * 1983-06-10 1984-12-22 ユニチカ株式会社 抗菌剤徐放性導尿カテ−テル
US4582873A (en) * 1984-05-21 1986-04-15 Ppg Industries, Inc. Process for producing aqueous dispersions, internally silylated and dispersed polyurethane resins, and surfaces containing same
JPS61283612A (ja) * 1985-06-10 1986-12-13 Nippon Oil & Fats Co Ltd 耐擦傷性コ−テイング組成物
JPH0665761B2 (ja) * 1986-02-04 1994-08-24 東洋紡績株式会社 ポリエステル系ウレタン弾性糸の製造方法
JPH07107204B2 (ja) * 1986-10-22 1995-11-15 東洋紡績株式会社 ポリエステル系ウレタン弾性糸
JP3970955B2 (ja) * 1995-04-25 2007-09-05 三井化学ポリウレタン株式会社 ポリウレタン水性組成物
AUPO787897A0 (en) * 1997-07-14 1997-08-07 Cardiac Crc Nominees Pty Limited Silicon-containing chain extenders
US6299980B1 (en) * 1998-09-29 2001-10-09 Medtronic Ave, Inc. One step lubricious coating

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0153414A1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109661382A (zh) * 2016-09-20 2019-04-19 Usg内部有限责任公司 用于改善吸音板性能的硅酸盐涂料及其制备方法
CN109661382B (zh) * 2016-09-20 2022-10-11 Usg内部有限责任公司 用于改善吸音板性能的硅酸盐涂料及其制备方法
CN114767944A (zh) * 2022-03-14 2022-07-22 四川大学华西医院 具备超亲水能力的抗菌抗凝涂层材料及其制备方法与应用
CN114767944B (zh) * 2022-03-14 2023-06-20 四川大学华西医院 具备超亲水能力的抗菌抗凝涂层材料及其制备方法与应用

Also Published As

Publication number Publication date
MXPA02004673A (es) 2004-09-10
AU4835300A (en) 2001-07-31
JP4667698B2 (ja) 2011-04-13
JP2004529208A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
US6596401B1 (en) Silane copolymer compositions containing active agents
WO2001053414A1 (fr) Compositions copolymeres de silane renfermant des principes actifs
CA2639838C (fr) Enduit lubrifiant antimicrobien
CA2693139C (fr) Catheter de foley a barriere sterile
CA2394214C (fr) Compositions polymeres contenant des colloides de sels d'argent
AU2004283726B2 (en) Lubricant compositions, their preparation and articles coated therewith
US20100074932A1 (en) Antimicrobial compositions containing gallium
JP4667698B2 (ja) 活性物質を含有するシランコポリマー組成物
AU2002246277B2 (en) Lubricious coating comprising pharmacological additives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040915

17Q First examination report despatched

Effective date: 20040915

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100420